Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Conversations with Giants in Medicine

Bruce Spiegelman

More than almost any other scientist in the field of obesity and metabolism research, the work of Bruce Spiegelman, from the Dana-Farber Cancer Institute and Harvard Medical School, has informed potential targets for drug discovery that could burn fat and even turn fat into muscle. He was the first to suggest that inflammation underscores insulin resistance, and also the first to find the key regulator of adipogenesis, PPAR-γ.


Paul Greengard

If you, or someone you know, has Parkinson’s disease, mental health issues, or other neurological disorders, medication can often help. The bulk of these medications have been established based on the work of neuroscientist Paul Greengard from the Rockefeller University, who worked out just how the brain responds to neurotransmitters — the chemicals that help the brain signal. Most of what most neuroscientists know today about neurotransmission, and specifically the dynamics of slow synaptic transmission, is predicated on the work of Dr. Greengard. The interview features stories about his seminal research discoveries and his competitive streak in potato sack races.


Jeffrey Friedman

Dr. Jeffrey Friedman, of Rockefeller University, has been at the center of discovery of the molecular determinants of why we eat what we eat and, more importantly, why we eat so much of what we eat. Over the last three decades, now almost daily in the media, alarm has been sounded about the growing obesity epidemic. Dr. Friedman has spent his research career engaged in the discovery and characterization of leptin, one of the most important hormones regulating appetite and hunger.


Eugene Braunwald

Dr. Eugene Braunwald has often been called the father of modern cardiology. Science Watch has listed Dr. Braunwald as the most frequently cited author in cardiology. Beyond numerous awards and 20 honorary degrees, he was the first cardiologist elected to the National Academy of Sciences. Nobel Prize winners in medicine have named Braunwald as the person who has contributed the most to cardiology in recent years. He speaks today about his trajectory from Nazi-occupied Austria through his immigrant struggle in New York City to land as the Chairman of Medicine at Harvard Medical School.


Thomas Starzl

Today in the United States, more than 6,000 people a year receive a liver transplant, and since liver transplants have begun, over 200,000 patients have received this therapy. They survive today due to the efforts of a legendary scientist and surgeon: Thomas Starzl of the University of Pittsburgh Medical Center. He performed the first successful liver transplant in 1967 and refined the use of immunosuppressive drugs such that patients could tolerate their grafts — some for decades. With Starzl’s efforts over the last 50 years, thousands of patients with end-stage liver disease have been able to live long and active lives.

  • ← Previous
  • 1
  • 2
  • …
  • 12
  • 13
  • 14
  • 15
  • Next →
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts